Financial Performance - The company's operating revenue for Q1 2023 was CNY 436,759,573.82, representing a year-on-year increase of 3.30%[3] - Net profit attributable to shareholders was CNY 63,786,808.29, showing a significant increase of 86.45% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 49,170,758.24, up by 100.58% year-on-year[3] - Basic earnings per share for the period was CNY 0.15, reflecting an increase of 88.21% compared to the previous year[3] - The weighted average return on equity was 4.49%, an increase of 1.67 percentage points year-on-year[3] - Total operating revenue for Q1 2023 was CNY 436,759,573.82, an increase of 3.9% compared to CNY 422,803,032.95 in Q1 2022[20] - Net profit for Q1 2023 was CNY 63,037,123.91, up 100.5% from CNY 31,343,677.50 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.15, compared to CNY 0.08 in Q1 2022, representing an increase of 87.5%[22] - The company reported a profit before tax of CNY 72,299,752.37, compared to CNY 35,808,330.41 in Q1 2022, an increase of 101.3%[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,983,131,860.61, up 2.09% from the end of the previous year[3] - As of March 31, 2023, the total assets of the company amounted to RMB 2,983,131,860.61, an increase from RMB 2,922,150,136.69 at the end of 2022, reflecting a growth of approximately 2.1%[16] - The company reported a total current liabilities of RMB 952,615,299.33, a decrease from RMB 999,587,401.38, reflecting a reduction of about 4.7%[17] - The company’s total liabilities decreased to RMB 1,255,466,225.60 from RMB 1,297,444,234.03, reflecting a decline of about 3.2%[17] - The total liabilities amounted to CNY 1,392,481,793.06, a slight decrease from CNY 1,414,201,204.10 in the previous year[18] Cash Flow - The company reported a net cash flow from operating activities of -CNY 63,977,691.55, indicating a shift from positive to negative cash flow[3] - Cash inflow from operating activities totaled CNY 378,269,536.20, down from CNY 477,571,424.27 in the previous year, a decrease of 20.8%[24] - The net cash flow from operating activities was -$63.98 million, a decrease from $39.25 million in the previous period[25] - Total cash outflow from operating activities amounted to $442.25 million, slightly up from $438.32 million year-over-year[25] - Cash inflow from investment activities totaled $47.96 million, down from $78.08 million in the previous period[25] - The net cash flow from investment activities was -$55.05 million, compared to -$35.46 million in the previous period[25] - Cash inflow from financing activities was $84.33 million, a decrease from $126.35 million year-over-year[25] - The net cash flow from financing activities was -$79.61 million, compared to a positive $19.10 million in the previous period[25] - The ending cash and cash equivalents balance was $184.79 million, down from $279.62 million in the previous period[25] Equity and Investments - Shareholders' equity attributable to the parent company increased to CNY 1,459,415,824.17, a rise of 4.98% from the previous year[3] - Total equity attributable to shareholders increased to CNY 1,459,415,824.17 from CNY 1,390,129,348.50, reflecting a growth of 5.0%[18] - The company’s long-term equity investments increased to RMB 256,735,406.63 from RMB 252,067,896.85, showing a growth of approximately 1.1%[17] - The company’s goodwill rose to RMB 273,983,187.99 from RMB 246,437,637.43, representing an increase of about 11.2%[17] Operational Changes - The increase in net profit was attributed to enhanced product marketing and academic promotion efforts, with the pharmaceutical sector achieving a revenue growth of 22.63%[5] - The company plans to continue focusing on its "338 major product development plan" to drive further growth and efficiency improvements[5] - The company established a new subsidiary, Guangdong Jida Gene Drug Engineering Research Center Co., Ltd., with a registered capital of RMB 7.3 million, holding a 73% equity stake[12] Costs and Expenses - Total operating costs decreased to CNY 383,173,514.19 from CNY 396,051,045.50, reflecting a reduction of approximately 3.5%[20] - Research and development expenses increased to CNY 17,590,859.46 from CNY 16,913,581.31, indicating a growth of 4.0%[21] - The company paid $76.40 million in employee-related cash payments, compared to $99.56 million in the previous period[25] - The company reported a total tax payment of $59.04 million, an increase from $42.57 million year-over-year[25] - Cash outflow for the acquisition of fixed assets was $55.45 million, up from $40.26 million in the previous period[25]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com）； 会议召开方式：上证路演中心网络互动； 证券代码：603998 证券简称：方盛制药 公告编号：2023-042 湖南方盛制药股份有限公司 关于召开2022年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）下午 16:00—17:00； 第 1 页，共 2 页 投资者可于 2023 年 5 月 10 日（星期三）至 5 月 16 日（星期二）16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com， 603998@fangsheng.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 湖南方盛制 ...

Financial Performance - The company's operating revenue for 2022 was RMB 1,792,000,925.51, representing a 14.36% increase from RMB 1,566,972,727.99 in 2021 [25]. - Net profit attributable to shareholders for 2022 was RMB 285,851,485.43, a significant increase of 308.12% compared to RMB 70,040,562.22 in 2021 [26]. - The basic earnings per share for 2022 was RMB 0.66, reflecting a 312.50% increase from RMB 0.16 in 2021 [27]. - The total assets at the end of 2022 amounted to RMB 2,922,150,136.69, an 8.05% increase from RMB 2,704,474,688.10 at the end of 2021 [26]. - The net cash flow from operating activities for 2022 was RMB 301,625,891.42, which is a 62.49% increase from RMB 185,626,591.50 in 2021 [26]. - The weighted average return on equity for 2022 was 19.24%, up from 5.98% in 2021, indicating a significant improvement [27]. - The net profit after deducting non-recurring gains and losses for 2022 was RMB 106,519,926.79, a 69.03% increase from RMB 63,020,050.07 in 2021 [26]. - The company's net assets attributable to shareholders at the end of 2022 were RMB 1,390,129,348.50, a 16.23% increase from RMB 1,196,044,862.87 at the end of 2021 [26]. Dividend and Shareholder Returns - The board approved a cash dividend of 2.60 CNY per 10 shares for all shareholders, subject to shareholder meeting approval [5]. Audit and Compliance - The financial report was audited and received a standard unqualified opinion from the accounting firm [4]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission [167]. - The company has not reported any related party transactions that could affect its independence [167]. Market Strategy and Growth - The company plans to continue expanding its market presence and investing in new product development to sustain growth [27]. - The company aims to enhance its core competitiveness through innovation in traditional Chinese medicine and management transformation [71]. - The company is actively pursuing market expansion through the establishment of new subsidiaries and related transactions [188]. - The company plans to enhance academic promotion and terminal coverage for its pediatric product, Xiaoer Jingxing Cough Granules, to boost sales growth [60]. - The company aims to develop 3 products with a revenue of 1 billion, 3 products with 500 million, and 8 products exceeding 100 million within the next 5-10 years as part of the "338 Major Product Development Plan" [150]. Research and Development - The company has established an Innovation Research Institute to enhance R&D capabilities, focusing on a multi-center development model for innovative traditional Chinese medicine [151]. - The company focuses on the research and development of traditional Chinese medicine and has developed several brand series, including "Xinxuean" for cardiovascular diseases and "Jinbeibei" for pediatrics [71]. - The company has 141 drug registration certificates and 17 new drug certificates, indicating a strong product reserve to support strategic goals [72]. - The company is actively involved in various clinical trials, including the ongoing clinical research for the pediatric cough granules and the application review for Nolitong granules [134]. Operational Efficiency - The company has successfully reduced production costs for key raw materials, enhancing overall profitability and operational efficiency [37]. - The company has implemented a comprehensive safety management system, achieving a 100% safety hazard rectification rate and no major safety incidents during the reporting period [43]. - The company has initiated a group management enhancement project to optimize organizational structure and improve operational efficiency [44]. Employee Management and Development - The company has focused on talent acquisition and training, establishing a performance-based incentive system to enhance employee engagement and loyalty [45]. - The company emphasizes a performance-oriented "three-dimensional" incentive system to enhance employee motivation and align with long-term development goals [199]. - Comprehensive training programs are provided to support employees' career development and skill enhancement [200]. Industry Trends and Market Conditions - The pharmaceutical industry in China continues to grow, supported by government policies promoting research and innovation, with a strong emphasis on traditional Chinese medicine [46]. - The total revenue of the top 100 pharmaceutical companies in China reached CNY 1,076.2 billion in 2021, marking a year-on-year growth of 19.40% [52]. - The market for pediatric traditional Chinese medicine (TCM) has shown stable growth, with a terminal sales scale of 10.4 billion RMB in 2021, a 43% increase from 2015 [58]. Financial Management - The company reported a significant increase in contract liabilities, which rose by 149.26% to ¥87.45 million, mainly due to pre-receipts from customers [110]. - The company’s total liabilities decreased by 52.60% to ¥210.25 million, reflecting a strategic adjustment in its borrowing structure [110]. - The company has made provisions for asset impairment and bad debt reserves in its financial reports [186]. Governance and Board Activities - The company conducted 16 board meetings and 13 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements [163][164]. - The company held a total of 3 shareholder meetings during the reporting period, with all proposed resolutions approved [169]. - The company has undergone changes in its board composition, with several members resigning and new members being elected [183]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies [173]. - The company anticipates a recovery in the pharmaceutical industry, driven by ongoing reforms and policy support, indicating a positive outlook for growth in the sector [148].

2022-001 证券代码：603998 证券简称：方盛制药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------|------------------------------|--------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | 参与单位名称 | | | | （排名不分先 | | 华安证券、瀚伦投资、永赢基金、红土创新、长安基金 | | 后） | | | | 时间 2022 | 年 4 月 29 | 日 14:00-15:00 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | | | | | 一、公司业务情况介绍 | | ...

证券代码：603998 证券简称：方盛制 药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： 2022-002 | --- | --- | --- | |-------------------|----------------------|------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | | | 华鑫证券、富唐资产、诺德基金、金百镕投资、天弘基金、君和资 | | 参与单位名称 | | 本、嘉合基金、上海天猊投资、中新融创、中科沃土、中原英石基 | | （排名不分先 | | 金、国海富兰克林、华宝信托、南方睿泰基金、理成资产、上海国 | | 后） | 际信托、泰康资产等 | | | 时间 2022 | 年 5 月 5 日 | 10:30-11:30 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公 ...

证券代码：603998 证券简称：方盛制药 编号：2022-004 湖南方盛制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n 新闻发布会 \n 现场参观 \n 其他 | 分析师会议 \n 业绩说明会 \n 路演活动 \n 电话会议 | | 参与单位名称 | 华鑫证券俞家宁 | | | 时间 2022 | 年 6 月 1 日 | 15:00-17:30 | | | 地点 公司会议室 | | | 会议形式 现场调研 | | | | 上市公司接待人 员姓名 | 董事会秘书何仕 | | | | 主要交 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2022-104 湖南方盛制药股份有限公司 关于参加湖南辖区上市公司2022年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管 理工作，湖南方盛制药股份有限公司（以下简称"公司"）将参 加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会 与深圳市全景网络有限公司联合举办的"湖南辖区上市公司2022 年投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限 公司提供的互联网平台举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net）参与本次投资者网上集体接待日活动，活 动时间为：2022年9月29日（星期四）15:30至16:55。 届时公司董事会秘书何仕先生、证券事务代表曾博茹女士将 通过网络在线问答互动的形式 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2021-088 湖南方盛制药股份有限公司 关于参加2021年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管 理工作，湖南方盛制药股份有限公司（以下简称"公司"）将参 加由中国证券监督管理委员会湖南监管局主办，湖南省上市公司 协会与深圳市全景网络有限公司协办的"2021年湖南辖区上市公 司投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司 提供的互联网平台举行，投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net）参与本次投资者集体接待日活动，活动 时间为：2021年9月24日（星期五）15:00至17:00。 届时公司董事会秘书何仕先生将通过网络在线问答互动的形 式，与投资者进行沟通和 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2020-070 湖南方盛制药股份有限公司 关于参加2020年度湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管 理工作，湖南方盛制药股份有限公司（以下简称"公司"）将参 加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会 与深圳市全景网络有限公司联合举办的"2020年度湖南辖区上市 公司投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司 提供的互联网平台举行，投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net）或关注微信公众号（全景财经）参与本 次投资者集体接待日活动，活动时间为：2020年9月11日（星期五） 15:00至17:00。 届时公司总经理、董事会秘书肖汉卿先生，证券 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2019-063 湖南方盛制药股份有限公司 关于参加2019年湖南辖区上市公司投资者 网上接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管 理工作，湖南方盛制药股份有限公司（以下简称"公司"）将参 加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会 与深圳市全景网络有限公司联合举办的"2019年湖南辖区上市公 司投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司 提供的互联网平台举行，投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net）或关注微信公众号（全景财经）参与本 次投资者集体接待日活动，活动时间为：2019年9月10日（星期二） 下午15:00至17:00。 届时公司总经理、董事会秘书肖汉卿先生，证券事务 ...